Research
Every study, decoded.
24articles on peptides, GLP-1, longevity science, and biohacking. We read the trial data so you don't have to.
GLP-1
Tirzepatide vs. Semaglutide: The Head-to-Head Trial Results Are In
The SURMOUNT-5 trial compared tirzepatide and semaglutide head-to-head in 751 people. Tirzepatide delivered 47% more weight loss. Here's what the data shows.
3 May 2026
GLP-1
Retatrutide vs Tirzepatide vs Semaglutide: The Weight Loss Numbers Nobody Expected
Retatrutide hits 22-24% weight loss, tirzepatide reaches 18-22%, and semaglutide caps at 14-20%. A 2026 meta-analysis of 26 trials shows triple agonists beat dual agonists, which beat single GLP-1 drugs.
3 May 2026
GLP-1
Tirzepatide vs Semaglutide: More Weight Loss Doesn't Mean Better Outcomes
Tirzepatide causes more weight loss than semaglutide, but real-world data shows semaglutide reduces heart attack and stroke risk by 29%, independent of weight loss. Here's what that means.
3 May 2026
GLP-1
The GLP-1 Showdown: Which Drug Actually Protects Your Heart Better?
New 2025-2026 studies reveal tirzepatide and semaglutide protect your heart differently depending on whether you have diabetes, fatty liver, or existing heart disease, here's which one wins in each scenario.
3 May 2026
GLP-1
Retatrutide Just Posted 28.7% Weight Loss, Here’s What That Actually Means
Retatrutide’s TRIUMPH-4 readout paired 28.7% weight loss with a 75.8% drop in knee pain over 68 weeks. Here’s why the triple agonist signal matters for people stuck between obesity and osteoarthritis.
3 May 2026
GLP-1
Amycretin Is Basically CagriSema in One Molecule, Here’s Why the Phase 2 Diabetes Data Matters
Weekly amycretin shots dropped HbA1c by 1.8 points and weight by 14.5% while the oral pill still managed 10.1% weight loss in 36 weeks. Novo just moved it into Phase 3 diabetes trials for a reason.
3 May 2026
GLP-1
Orforglipron Is the Oral GLP-1 Contender Everyone With Needle Fatigue Has Been Waiting For
ACHIEVE and ATTAIN data show orforglipron dropping HbA1c by up to 2.1 points and delivering double-digit weight loss without injections, putting a true anytime oral GLP-1 on the runway for 2025–2026 approvals.
3 May 2026
GLP-1
Tirzepatide Is Now Being Tested for Type 1 Diabetes and Alcohol Use Disorder. Here's Why That's Wild.
Tirzepatide isn't just for weight loss anymore. 2026 trials are testing it for type 1 diabetes and alcohol use disorder, here's what the science shows.
3 May 2026
GLP-1
The GLP-1 Side Effect Nobody's Tracking (But 2026 Research Says You Should)
New 2026 research shows GLP-1 users have 29% higher osteoporosis risk over five years. Here's what's happening to your bones, and what you should do about it.
3 May 2026
GLP-1
GLP-1s Explained: Why 1 in 7 Americans Are Taking Them
GLP-1 agonists like semaglutide and tirzepatide are the most effective weight-loss drugs ever created. This guide explains how they work, what to expect, side effects, and who should use them.
10 March 2026